Peterson Gitonga Mathenge1, Soon Khai Low2, Nguyen Lam Vuong3, Muawia Yousif Fadlelmola Mohamed4, Hazem Abdelkarem Faraj5, Ghada Ibrahim Alieldin6, Rawan Al Khudari7, Nusaiba Adam Yahia8, Adnan Khan9, Omar Mohammad Diab10, Yara Mahmoud Mohamed11, Ahmad Helmy Zayan12, Gehad Mohamed Tawfik13, Nguyen Tien Huy14, Kenji Hirayama15. 1. Leading program, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan; Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan. 2. Online Research Club, Japan; School of Medicine, Faculty of Health and Medical Sciences, Taylor's University, Selangor, Malaysia. 3. Online Research Club, Japan; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. Electronic address: nguyenlamvuong@ump.edu.vn. 4. Online Research Club, Japan; Faculty of Medicine, University of Khartoum, Sudan. 5. Online Research Club, Japan; Faculty of Medicine, University of Tripoli, Tripoli, Libya. 6. Online Research Club, Japan; Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. 7. Online Research Club, Japan; Faculty of Medicine, Damascus University, Damascus, Syria. 8. Online Research Club, Japan; Faculty of Medicine, Omdurman Islamic University, Khartoum, Sudan. 9. Online Research Club, Japan; Paediatrics, Rehman Medical Institute, Peshawar, Pakistan. 10. Online Research Club, Japan; Jordan University of Science and Technology, Irbid, Jordan. 11. Online Research Club, Japan; Faculty of Medicine, Misr University for Science and Technology, Cairo, Egypt. 12. Online Research Club, Japan; Department of Otolaryngology, Menoufia University, Menoufia, Egypt. 13. Online Research Club, Japan; Faculty of Medicine, Ain Shams University, Cairo, Egypt. 14. Evidence Based Medicine Research Group, Ton Duc Thang University, Ho Chi Minh City 70000, Viet Nam; Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 70000, Viet Nam; Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki 852-8523, Japan. Electronic address: nguyentienhuy4@duytan.edu.vn. 15. Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, Japan. Electronic address: hiraken@nagasaki-u.ac.jp.
Abstract
BACKGROUND: Malaria parasites have developed resistance to most of the known antimalarial drugs in clinical practice, with reports of artemisinin resistance emerging in South East Asia (SEA). We sort to find the status of artemisinin resistance and efficacy of different modalities of the current artemisinin-based combination therapies (ACTs). METHODS: We carried out a systematic search in 11 electronic databases to identify in vivo studies published between 2001 and 2017 that reported artemisinin resistance. This was then followed by A network meta-analysis to compare the efficacy of different ACTs. Quality assessment was performed using the Cochrane Risk of Bias (ROB) tool for randomized controlled trials and National Institute of Health (NIH) tool for cross-sectional studies. The study protocol was registered in PROSPERO under number CRD42018087574. RESULTS: With 8400 studies initially identified, 82 were eligible for qualitative and quantitative analysis. Artemisinin resistance was only reported in South East Asia. K13 mutation C580Y was the most abundant mutation associated with resistance having an abundance of 63.1% among all K13 mutations reported. Although the overall network meta-analysis had shown good performance of dihydroartemisinin piperaquine in the early years, a subgroup analysis of the recent years revealed a poor performance of the drug in relation to recrudescence, clinical failure and parasitological failure especially in the artemisinin resistant regions. CONCLUSION: With report of high resistance and treatment failure against the leading artemisinin combination therapy in South East Asia, it is imperative that a new drug or a formulation is developed before further spread of resistance.
BACKGROUND:Malaria parasites have developed resistance to most of the known antimalarial drugs in clinical practice, with reports of artemisinin resistance emerging in South East Asia (SEA). We sort to find the status of artemisinin resistance and efficacy of different modalities of the current artemisinin-based combination therapies (ACTs). METHODS: We carried out a systematic search in 11 electronic databases to identify in vivo studies published between 2001 and 2017 that reported artemisinin resistance. This was then followed by A network meta-analysis to compare the efficacy of different ACTs. Quality assessment was performed using the Cochrane Risk of Bias (ROB) tool for randomized controlled trials and National Institute of Health (NIH) tool for cross-sectional studies. The study protocol was registered in PROSPERO under number CRD42018087574. RESULTS: With 8400 studies initially identified, 82 were eligible for qualitative and quantitative analysis. Artemisinin resistance was only reported in South East Asia. K13 mutation C580Y was the most abundant mutation associated with resistance having an abundance of 63.1% among all K13 mutations reported. Although the overall network meta-analysis had shown good performance of dihydroartemisinin piperaquine in the early years, a subgroup analysis of the recent years revealed a poor performance of the drug in relation to recrudescence, clinical failure and parasitological failure especially in the artemisinin resistant regions. CONCLUSION: With report of high resistance and treatment failure against the leading artemisinin combination therapy in South East Asia, it is imperative that a new drug or a formulation is developed before further spread of resistance.
Authors: Aditya H Gaur; John C Panetta; Amber M Smith; Ronald H Dallas; Burgess B Freeman; Tracy B Stewart; Li Tang; Elizabeth John; Kristen C Branum; Nehali D Patel; Shelley Ost; Ryan N Heine; Julie L Richardson; Jared T Hammill; Lidiya Bebrevska; Fabian Gusovsky; Noritsugu Maki; Toshiharu Yanagi; Patricia M Flynn; James S McCarthy; Stephan Chalon; R Kiplin Guy Journal: EBioMedicine Date: 2022-05-19 Impact factor: 11.205
Authors: Dan Yang; Yang He; Bo Wu; Yan Deng; Menglin Li; Qian Yang; Liting Huang; Yaming Cao; Yang Liu Journal: J Adv Res Date: 2019-09-06 Impact factor: 10.479